Vertex Pharmaceuticals (VRTX) EBITDA Margin Growth (1y) (2010 - 2026)
Analysis
Vertex Pharmaceuticals (VRTX) EBITDA Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | -1,651.00 |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 29,091.00 |
| 10 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | -194.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -143.00 |
| Mar 31, 2026 | 1,536.00 |
| Dec 31, 2025 | 257.00 |
| Sep 30, 2025 | -171.00 |
| Jun 30, 2025 | 17,168.00 |
| Mar 31, 2025 | -1,961.00 |
| Dec 31, 2024 | -403.00 |
| Sep 30, 2024 | -153.00 |
| Jun 30, 2024 | -17,402.00 |
| Mar 31, 2024 | 955.00 |
| Dec 31, 2023 | -562.00 |
| Sep 30, 2023 | -647.00 |
| Jun 30, 2023 | -921.00 |
| Mar 31, 2023 | -1,682.00 |
| Dec 31, 2022 | 253.00 |
| Sep 30, 2022 | -488.00 |
| Jun 30, 2022 | 5,249.00 |
| Mar 31, 2022 | -186.00 |
| Dec 31, 2021 | -347.00 |
| Sep 30, 2021 | 945.00 |